Guinea-Bissau canceled a controversial US-funded trial on newborns, highlighting the tension between scientific inquiry and public trust in globally recommended vaccines.
AI-generated summary. Check the original reporting for context and accuracy.
This is the available feed excerpt, which may be shortened or in the publisher’s original language.
Government officials in Guinea-Bissau have formally rejected a clinical trial that would be run by Danish researchers and funded by the US to look for alleged nonspecific harms from the newborn dose of the hepatitis B vaccine. The vaccine dose is currently recommended globally for all newborns and has been used safely and effectively for decades. In an email to Ars Technica, one of the trial's lead researchers, Christine Stabell Benn of Bandim Health Project and the University of Southern Denmark, said that Guinea-Bissau's Council of Ministers "formally reaffirmed its non-acceptance of the study on 16 October." The revelation that the study was formally rejected last week comes after news on Monday that judicial police in Guinea-Bissau raided Bandim Health's offices and seized vaccines. Stabell Benn highlighted that the police search came after the trial was rejected.Read full article Comments
An automated sorting aid based on source trust, keywords, and entities, on a scale of 1–12. High: 9–12; medium: 6–8; low: 1–5. It does not measure urgency, verify reporting, or indicate editorial endorsement.
Meta’s updated terms fail to stop AI scraping because broad language still allows it to harvest entire news sites, leaving publishers vulnerable despite recent tweaks.
Meta re-enabled Muse sharing after researchers exposed a security flaw allowing public discovery of private conversations, highlighting significant privacy risks in the platform's design.
The FCC is using new authority to ban devices containing chips from companies deemed national security threats, marking a significant expansion of its regulatory power over consumer electronics.